Navigation Links
Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
Date:10/24/2013

16.5 14% 1% Total revenues 3,673.0 3,480.0 6% 100%

Unaudited results for the three months to September 30, 2013

Non GAAP reconciliation

3 months to September Non 30, 2013 US GAAP Adjustments GAAP (a) (b) (c) (d) (e) $M $M $M $M $M $M $M Total revenues 1,236.6 - - - - - 1,236.6 Costs and expenses: Cost of product sales 197.1 - - - - (11.0) 186.1 R&D 229.1 - - - - (6.3) 222.8 SG&A 441.1 (44.4) - - (8.5) (16.5) 371.7 Gain on sale of product rights (3.6) - - 3.6 - - - Reorganization costs 13.7 - - (13.7) - - - Integration and acquisition costs 18.4 - (18.4) - - - - Depreciation - - - - - 33.8 33.8 Total operating expenses 895.8 (44.4) (18.4) (10.1) (8.5) - 814.4 Operating income 340.8 44.4 18.4 10.1 8.5 - 422.2 Interest income 0.4 - - - - - 0.4 Interest expense (9.0) - - - - - (9.0) Other income, net 0.6 - - - - - 0.6 Total other expense, net (8.0) - - - - - (8.0) Income before income taxes and equity in losses of equity method investees 332.8 44.4 18.4 10.1 8.5 - 414.2 Income taxes (54.3) (14.1) (1.0) (4.2) (3.1) - (76.7) Equity in losses of equity method investees, net of tax (0.3) - - - - - (0.3) Net income 278.2 30.3 17.4 5.9 5.4 - 337.2 Impact of convertible debt, net of tax 7.6 - - - - - 7.6 Numerator for diluted EPS 285.8 30.3 17.4 5.9 5.4 - 344.8 Weighted average number of shares (millions) - diluted 585.7 - - - - - 585.7 Diluted earnings per ADS 146.4c 15.6c 9.0c 3.0c 2.7c - 176.7c

The following items are included in Adjustments:

  1. Amortization and asset impairments: Amortization of intangible assets relating to intellectual property rights acquired ($44.4 million), and tax effect of adjustments;
  2. Acquisition and integration activities: Costs primarily associated with the integration of SARcode and Premacure ($3.7 million), charges related to the change in fair value of contingent consideration ($14.7 million), and tax effect of adjustments;
  3. '/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
11. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited ... seminar on probiotics in San Diego, CA. , The ... for health care professionals. This year’s pre-conference seminar was held ... health. Dr. Leyer spoke about the emerging topics and science ...
(Date:1/22/2015)... BRUNSWICK , Nueva Jersey , 22 de ... Award for Biomedical Research abre hoy su llamada a ... personas cuya investigación científica ha hecho, o tiene el ... la salud humana. Las nominaciones se aceptarán hasta el ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... Cardium Therapeutics (NYSE Amex: CXM ) today announced ... U.S. Food and Drug Administration (FDA) seeking marketing clearance ... XL is an advanced wound care management medical ... for use by physicians in patients with topical wounds, ...
... , BENLYSTA(TM) Successful in Second Pivotal Clinical Trial ... (HGS) and GlaxoSmithKline (GSK) today announced positive results from ... trials of BENLYSTA(TM) (belimumab) for treating systemic lupus. ... shared at the 73rd Annual Scientific meeting of the ...
... , KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ ... ) announced today the U.S. Food and Drug ... to the company,s supplemental Biologics License Application regarding ... of patients with stage III malignant melanoma after ...
Cached Biology Technology:Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 3Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 4Promise of a New Lupus Treatment Is a Groundbreaking Achievement 2Promise of a New Lupus Treatment Is a Groundbreaking Achievement 3U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma 2U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma 3U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma 4U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma 5U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma 6
(Date:12/17/2014)... fundamentally transforming the travel experience and nowhere is this ... decade, ePassports, biometric readers, and secure document scanners have ... via eGates and Automated Passport Control (APC) Kiosks at ... across the globe. According to ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... advances in technology, it is important to upgrade biometric ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... storage and use of surplus blood samples taken from newborns ... explicit to non-existent, leaving many parents ill-informed about how their ... team led by a member of the Johns Hopkins Berman ... of Utah. A report on their analysis of the subject ...
... Delhi, India The Indian Government today released new tiger ... numbers have increased in the country that has half of ... tiger numbers in India at 1,706, up from 1,411 during ... an additional tiger reserve in the count, the Sundarbans, that ...
... been the leaders in the use of intra-arterial yttrium-90 ... cancer. Now, new results from a large multi-institutional study ... Y-90 than previously tried is safe, provides results when ... can be done on an outpatient basis. This study, ...
Cached Biology News:Most states unclear about storage, use of babies' blood samples, new study finds 2Most states unclear about storage, use of babies' blood samples, new study finds 3Most states unclear about storage, use of babies' blood samples, new study finds 4India releases tiger numbers as experts convene 2Interventional Radiology Y-90 Liver Cancer-busting Treatment: Safe, Fast, Extends Life 2Interventional Radiology Y-90 Liver Cancer-busting Treatment: Safe, Fast, Extends Life 3
...
...
... Specificity: This antibody recognizes murine ... cross-react with other related IRF ... with murine IRF7 protein was ... of the 293T cells transfected ...
...
Biology Products: